Amgen, Inc. (NASDAQ:AMGN) is Principle Wealth Partners LLC’s 4th Largest Position

Principle Wealth Partners LLC boosted its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 574.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 57,902 shares of the medical research company’s stock after buying an additional 49,312 shares during the quarter. Amgen accounts for approximately 3.9% of Principle Wealth Partners LLC’s investment portfolio, making the stock its 4th largest position. Principle Wealth Partners LLC’s holdings in Amgen were worth $11,205,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Gifford Fong Associates lifted its position in shares of Amgen by 25.3% during the second quarter. Gifford Fong Associates now owns 67,671 shares of the medical research company’s stock worth $12,470,000 after purchasing an additional 13,671 shares during the last quarter. Bray Capital Advisors lifted its position in shares of Amgen by 11.6% during the second quarter. Bray Capital Advisors now owns 19,676 shares of the medical research company’s stock worth $3,626,000 after purchasing an additional 2,045 shares during the last quarter. CHICAGO TRUST Co NA lifted its position in shares of Amgen by 2.8% during the second quarter. CHICAGO TRUST Co NA now owns 3,716 shares of the medical research company’s stock worth $685,000 after purchasing an additional 100 shares during the last quarter. Private Advisor Group LLC lifted its position in shares of Amgen by 4.0% during the second quarter. Private Advisor Group LLC now owns 38,488 shares of the medical research company’s stock worth $7,093,000 after purchasing an additional 1,494 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Amgen during the second quarter worth $15,515,000. 76.33% of the stock is owned by institutional investors.

In other Amgen news, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $215.45, for a total value of $91,566.25. Following the completion of the transaction, the director now directly owns 5,413 shares of the company’s stock, valued at $1,166,230.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Cynthia M. Patton sold 13,426 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $208.07, for a total value of $2,793,547.82. Following the completion of the transaction, the senior vice president now directly owns 32,648 shares of the company’s stock, valued at $6,793,069.36. The disclosure for this sale can be found here. Insiders sold 17,851 shares of company stock valued at $3,685,674 over the last three months. 0.25% of the stock is currently owned by corporate insiders.

Several analysts have recently weighed in on AMGN shares. Mizuho reiterated a “hold” rating and set a $212.00 target price on shares of Amgen in a research report on Sunday, September 29th. Credit Suisse Group reiterated an “outperform” rating and set a $225.00 target price (up from $202.00) on shares of Amgen in a research report on Friday, August 16th. Leerink Swann lifted their price objective on Amgen from $189.00 to $205.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. William Blair restated a “hold” rating on shares of Amgen in a report on Friday, August 30th. Finally, Bank of America began coverage on Amgen in a report on Wednesday, October 16th. They issued a “neutral” rating and a $215.00 price objective for the company. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $219.56.

Shares of AMGN stock traded up $3.12 on Friday, hitting $221.11. The stock had a trading volume of 2,069,900 shares, compared to its average volume of 2,911,719. The business has a 50 day moving average price of $202.75 and a 200 day moving average price of $188.90. The company has a market cap of $127.80 billion, a PE ratio of 15.35, a P/E/G ratio of 2.21 and a beta of 1.09. Amgen, Inc. has a one year low of $166.30 and a one year high of $221.25. The company has a quick ratio of 2.59, a current ratio of 2.89 and a debt-to-equity ratio of 2.54.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, October 29th. The medical research company reported $3.66 EPS for the quarter, beating the Zacks’ consensus estimate of $3.53 by $0.13. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. Amgen’s revenue for the quarter was down 2.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.69 earnings per share. Equities research analysts expect that Amgen, Inc. will post 14.44 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 6th. Shareholders of record on Friday, November 15th will be issued a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 2.62%. The ex-dividend date of this dividend is Thursday, November 14th. Amgen’s payout ratio is presently 40.28%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: How to Track your Portfolio in Google Finance

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply